Filtered By:
Education: Study
Management: Centers for Disease Control and Prevention (CDC)
Vaccination: Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 17 results found since Jan 2013.
COVID-19 Can Cause New Cholesterol Problems. What to Know
Not long after the start of the global coronavirus pandemic, it was apparent that many people infected with SARS-CoV-2 were developing persistent and, in some cases, debilitating health problems. Now known widely as post-Covid syndrome or Long COVID, the most common symptoms of this condition are fatigue, attention problems, headaches, muscle or joint pain, and weakness. But those are just the start. Medical researchers have also linked SARS-CoV-2 to lingering complications in multiple organs and systems, and some recent work has found that new-onset cholesterol problems may be an under-recognized but common complication o...
Source: TIME: Health - May 30, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate heart health Source Type: news
The U.S. Still Doesn ’ t Have Good COVID-19 Data. Here ’ s Why That ’ s a Problem
Check the COVID-19 Data Tracker from the U.S. Centers for Disease Control and Prevention (CDC), and you’ll get a rundown of the latest case numbers, hospitalizations, and deaths. Those categories might seem straightforward, but the data, say many experts, are telling us a lot less than we think they are.
That’s because it’s getting increasingly difficult to parse who is hospitalized or dies from COVID-19, and who is hospitalized or dies from another reason but with COVID-19. Across the U.S., “COVID-19 hospitalizations” represent all kinds of patients: those who need hospital-level care for sev...
Source: TIME: Health - January 30, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
FDA Experts Vote to Make All COVID-19 Vaccines and Boosters Bivalent
In a unanimous decision, all 21 voting members of the U.S. Food and Drug Administration’s (FDA) vaccine committee recommended that the U.S. start using the same COVID-19 virus strain in all of the COVID-19 vaccines, including primary and booster doses.
That means the bivalent booster dose, which targets both the original SARS-CoV-2 strain and the Omicron BA.4/5 strains, would soon become the only type used for all primary shots and boosters.
The decision reflects a turning point in the pandemic. Until now, vaccine makers have tried to keep up with constantly evolving variants, but they’ve always been a few step...
Source: TIME: Health - January 27, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
COVID-19, Overdoses Made 2021 The Deadliest Year in U.S. History
2021 was the deadliest year in U.S. history, and new data and research are offering more insights into how it got that bad.
The main reason for the increase in deaths? COVID-19, said Robert Anderson, who oversees the Centers for Disease Control and Prevention’s work on death statistics.
The agency this month quietly updated its provisional death tally. It showed there were 3.465 million deaths last year, or about 80,000 more than 2020’s record-setting total.
Early last year, some experts were optimistic that 2021 would not be as bad as the first year of the pandemic — partly because effective COVID-19 vac...
Source: TIME: Health - April 12, 2022 Category: Consumer Health News Authors: MIKE STOBBE / AP Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news
COVID-19 Exposed the Faults in America ’s Elder Care System. This Is Our Best Shot to Fix Them
For the American public, one of the first signs of the COVID-19 pandemic to come was a tragedy at a nursing home near Seattle. On Feb. 29, 2020, officials from the U.S. Centers for Disease Control and Prevention (CDC) and Washington State announced the U.S. had its first outbreak of the novel coronavirus. Three people in the area had tested positive the day before; two of them were associated with Life Care Center of Kirkland, and officials expected more to follow soon. When asked what steps the nursing home could take to control the spread, Dr. Jeff Duchin, health officer for Seattle and King County, said he was working w...
Source: TIME: Health - June 15, 2021 Category: Consumer Health News Authors: Abigail Abrams Tags: Uncategorized Aging COVID-19 feature franchise Magazine TIME for Health Source Type: news
This County Tried to Ensure Racial Equity in COVID-19 Vaccinations. The State Said No
It takes about eight minutes to try and save a life.
Or at least that’s how long it takes a volunteer with a tablet, standing in the parking lot at the T.R. Hoover Community Development center in South Dallas on a bitterly cold February morning. During the pandemic, the small nonprofit situated in the neighborhood that developers in the 1920s dubbed “the Ideal community” has taken on an ever evolving list of roles. It’s a job-search center. It’s a drive-through food pantry. And, of late, T.R. Hoover is an in-person coronavirus vaccine registration site aimed at helping Ideal’s mainly Bla...
Source: TIME: Health - March 2, 2021 Category: Consumer Health News Tags: Uncategorized COVID-19 feature Source Type: news
When a Texas County Tried to Ensure Racial Equity in COVID-19 Vaccinations, It Didn ’t Go as Planned
It takes about eight minutes to try and save a life.
Or at least that’s how long it takes a volunteer with a tablet, standing in the parking lot at the T.R. Hoover Community Development center in South Dallas on a bitterly cold February morning. During the pandemic, the small nonprofit situated in the neighborhood that developers in the 1920s dubbed “the Ideal community” has taken on an ever evolving list of roles. It’s a job-search center. It’s a drive-through food pantry. And, of late, T.R. Hoover is an in-person coronavirus vaccine registration site aimed at helping Ideal’s mainly Bla...
Source: TIME: Health - March 2, 2021 Category: Consumer Health News Authors: Janell Ross/Dallas Tags: Uncategorized COVID-19 feature Source Type: news
Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson Launches Heartline ™, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke
New Brunswick, NJ, February 25, 2020 — Johnson & Johnson (NYSE: JNJ) today announced that the Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Apple, opened enrollment for the Heartline™ Study. The study is designed to explore if the Heartline™ Study app on iPhone and heart health features on Apple Watch can improve health outcomes, including reducing the risk of stroke, with earlier detection of atrial fibrillation (AFib). AFib, a common form of irregular heart rhythm, is a leading cause of stroke in the U.S. To enroll in the Heartline™ Study, individuals must be age 65 or older...
Source: Johnson and Johnson - February 25, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
4-Year-Old Iowa Girl Blinded After Contracting the Flu
Jade DeLucia, a 4-year-old from Iowa, is back home with her family after being struck with a case of the flu that, after a lengthy hospital stay, has left her blind.
Amanda Phillips, the girl’s mother, told reporters that Jade came down with a fever in mid-December, which she initially controlled with medication. “There wasn’t any sign that would’ve told me that something was seriously wrong with her,” Phillips told CNN. Phillips did not immediately respond to TIME’s request for comment.
Jade had been vaccinated earlier in 2019, according to a post Phillips wrote on Facebook. But, she ad...
Source: TIME: Health - January 14, 2020 Category: Consumer Health News Authors: Jasmine Aguilera Tags: Uncategorized Iowa onetime public health Source Type: news
A bummer for kids: Nasal flu vaccine not effective
Follow me at @drClaire
Every year, many of my patients have been able to skip the needle — and still get vaccinated against the flu. That was the great thing about the nasal spray version of the flu vaccine, known as the LAIV (live attenuated influenza vaccine): kids scared of needles could get a squirt up each nostril and be all set.
This coming flu season, everyone is getting the shot.
It turns out that the nasal spray just didn’t work that well. Despite studies from the 2002-2003 and 2004-2005 flu seasons that seemed to show that the nasal spray actually worked better than the shot in children ages 2-8 years, over t...
Source: New Harvard Health Information - June 28, 2016 Category: Consumer Health News Authors: Claire McCarthy, MD Tags: Children's Health Cold and Flu Infectious diseases Parenting Prevention Source Type: news
Don’t shrug off shingles
If you had chickenpox as a kid, there is a good chance you may develop shingles later in life. “In fact, one in three is predicted to get shingles during their lifetime,” says Dr. Anne Louise Oaklander, director of the Nerve Unit at Harvard-affiliated Massachusetts General Hospital.
The same varicella-zoster virus that causes chickenpox also causes shingles. After the telltale spots of chickenpox vanish, the virus lies dormant in your nerve cells near the spinal cord and brain. When your immunity weakens from normal aging or from illnesses or medications, the virus can re-emerge. It then travels along a nerve to trigge...
Source: New Harvard Health Information - February 18, 2016 Category: Consumer Health News Authors: Matthew Solan Tags: Healthy Aging Infectious diseases Vaccines Source Type: news
